相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Infinite Epigenetics has acquired Tally Health in the largest deal in epigenetic age testing, creating a vertically integrated platform spanning advanced diagnostics and personalized longevity interventions. - The acquisition combines Infinite Epigenetics' scientific infrastructure and world's largest private DNA methylation datasets with Tally Health's consumer-focused longevity platform and proprietary intellectual property. - Tally Health will remain a standalone consumer brand under CEO Melanie Goldey, while leveraging the parent company's CLIA-certified laboratory and research partnerships with Harvard, Yale, Duke, and Stanford. - The combined entity aims to shift healthcare from reactive treatment to proactive, data-driven prevention by expanding epigenetics applications from research settings to mainstream healthcare.
- Yale researchers have discovered that nasal vaccine boosters can trigger robust immune responses in the respiratory tract without requiring adjuvants, offering a potential breakthrough for respiratory disease prevention. - The study demonstrates that simple viral protein antigens delivered nasally can effectively boost immunity at the primary site of viral entry, suggesting a safer approach to respiratory vaccine development. - These findings could significantly impact future vaccine strategies for diseases like COVID-19 by providing targeted protection where respiratory viruses first enter the body.
- A large real-world study of 26,635 advanced NSCLC patients found significant survival differences based on biomarker status, with ALK-positive patients achieving nearly 40 months median survival compared to 12-16 months for those without driver mutations. - Medication costs varied substantially by biomarker group, with the average annual treatment cost reaching $120,000 and two-year costs approximately $183,000 across all patients. - Patients without driver alterations showed consistently higher "cost per survivor" ratios, requiring about $500,000 to keep one low PD-L1 patient alive for two years versus $363,000 for ALK-positive patients. - The findings highlight critical gaps in community biomarker testing, where only 37% of NSCLC patients receive all nine recommended biomarker tests despite 83% having at least one test performed.
• The Pain Management Collaboratory Coordinating Center at Yale has received a six-year funding extension to continue its research on non-drug approaches for pain management. • The center's research focuses on veterans and active-duty military members, exploring treatments like chiropractic care, mindfulness, and physical therapy for pain and related conditions. • The collaboratory aims to bridge the gap between evidence-based nonpharmacological approaches and their limited use in routine clinical care, promoting access to high-quality pain care. • Studies involve over 11,000 veterans and military personnel, with the goal of expanding effective pain management strategies to broader populations.
- The FDA has authorized 950 AI medical devices as of August 2024, but current regulatory frameworks treat AI tools as devices rather than drugs, potentially leaving gaps in safety oversight and evaluation. - Major health systems including Yale, Harvard, and University of Michigan are implementing AI initiatives, while Microsoft launches new AI-powered healthcare suite, signaling rapid industry adoption. - Healthcare experts call for stronger regulatory oversight, including mandatory real-world performance reporting, transparency in AI decision-making, and a comprehensive public database of AI medical devices.
- A recent clinical trial indicates that Wegovy, a popular obesity drug, significantly reduces the risk of death from COVID-19 by 33%. - The study found that Wegovy's protective effect occurred rapidly, even before significant weight loss was achieved by participants. - Participants taking Wegovy also experienced a lower overall death rate from all causes, suggesting a broader impact on life expectancy for individuals with obesity. - Researchers emphasize that the randomized trial design provides strong evidence supporting Wegovy's potential benefits in mitigating COVID-19 mortality.
